Microbot Medical Updates Principal Executive Offices
Ticker: MBOT · Form: 8-K · Filed: Jan 18, 2024 · CIK: 883975
| Field | Detail |
|---|---|
| Company | Microbot Medical Inc. (MBOT) |
| Form Type | 8-K |
| Filed Date | Jan 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance
TL;DR
**Microbot Medical changed its office address, no big deal for the stock.**
AI Summary
Microbot Medical Inc. filed an 8-K on January 18, 2024, to update its principal executive offices to 288 Grove Street, Suite 388, Braintree, MA 02184, changing from 25 Recreation Park Dr, Suite 108, Hingham, MA 02043. This administrative change is a routine update and does not signal any operational shifts or financial impacts for the company. For investors, this simply means the company's mailing address has changed, which is unlikely to affect the stock's value or the company's business operations.
Why It Matters
This filing is a routine administrative update regarding Microbot Medical's physical address and has no direct impact on its financial performance or business strategy.
Risk Assessment
Risk Level: low — The filing reports a change in the company's principal executive offices, which is an administrative update and does not inherently carry financial or operational risk.
Analyst Insight
A smart investor would recognize this as a purely administrative update with no material impact on Microbot Medical's business or stock performance, thus requiring no immediate action.
Key Players & Entities
- Microbot Medical Inc. (company) — the registrant filing the 8-K
- 288 Grove Street, Suite 388 Braintree, MA 02184 (address) — new principal executive offices
- 25 Recreation Park Dr, Suite 108 Hingham, MA 02043 (address) — former principal executive offices
- January 18, 2024 (date) — date of earliest event reported
- MBOT (ticker) — trading symbol on NASDAQ Capital Market
FAQ
What is the primary purpose of this 8-K filing by Microbot Medical Inc.?
The primary purpose of this 8-K filing is to report a change in Microbot Medical Inc.'s principal executive offices, as indicated by the 'Date of earliest event reported: January 18, 2024' and the updated address information.
What was Microbot Medical Inc.'s previous principal executive office address?
Microbot Medical Inc.'s previous principal executive office address was 25 Recreation Park Dr, Suite 108, Hingham, MA 02043, as inferred from the change to the new address.
What is the new principal executive office address for Microbot Medical Inc.?
The new principal executive office address for Microbot Medical Inc. is 288 Grove Street, Suite 388, Braintree, MA 02184, as stated in the filing.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 18, 2024, as explicitly stated in the document.
Is Microbot Medical Inc. listed on a stock exchange, and if so, what is its trading symbol?
Yes, Microbot Medical Inc. is listed on the NASDAQ Capital Market under the trading symbol MBOT, as indicated in the 'Securities registered pursuant to Section 12(b) of the Act' section.
Filing Stats: 468 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-01-18 07:20:26
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value MBOT NASDAQ Capital Mark
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-24-002827.txt ( ) — 229KB
- mbot-20240118.xsd (EX-101.SCH) — 3KB
- mbot-20240118_lab.xml (EX-101.LAB) — 33KB
- mbot-20240118_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. MICROBOT MEDICAL INC. By: /s/ Harel Gadot Name: Harel Gadot Title: Chief Executive Officer, President and Chairman Date: January 18, 2024